14-day Premium Trial Subscription Sign Up For FreeGet Free

Biogen Inc. Stock Forecast NASDAQ:BIIB

Price Target and Analyst Ratings

Most Recent Rating

On September 16, 2021 "UBS Group" gave "$442.00 - $475.00" rating for BIIB. The price target was set to $299.21+1.1%.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-09-16 $442.00 - $475.00 Target Raised by UBS Group $299.69 $299.21+1.1%
2021-09-15 $400.00 - $360.00 Target Lowered by Bank of America $299.21 $301.23+1.8%
2021-08-02 $244.00 - $300.00 Target Raised by Mizuho $331.70 $326.73→0.7%
2021-07-27 $435.00 - $327.51 Reiterated by Cantor Fitzgerald $333.96 $333.34+0.4%
2021-07-27 $435.00 - $427.00 Target Lowered by Cantor Fitzgerald $333.96 $331.93+2.0%
2021-07-27 $359.00 - $423.00 Target Raised by Canaccord Genuity $333.96 $331.93+2.0%
2021-07-23 $453.00 - $455.00 Target Raised by Morgan Stanley $325.40 $320.22→1.9%
2021-07-23 $361.00 - $341.00 Target Lowered by Royal Bank of Canada $325.40 $326.36+1.1%
2021-07-22 $443.00 - $430.00 Target Lowered by Stifel Nicolaus $326.36 $327.87+1.5%
2021-07-19 $324.62 Target Set by Evercore ISI $324.16 $320.60→1.2%
2021-07-19 Reiterated by Evercore ISI $324.16 $324.62→1.1%
2021-07-16 $455.00 - $453.00 Target Lowered by Morgan Stanley $324.62 $326.20→0.6%
2021-07-11 Reiterated by Robert W. Baird $358.16 $358.16→3.0%
2021-07-11 $358.16 Target Set by Robert W. Baird $358.16 $358.16→3.0%
2021-06-28 Sector Perform Target Lowered by Royal Bank of Canada $340.27 $400.00 → $354.00
2021-06-18 Neutral - Overweight Upgraded by Piper Sandler $388.44 $384.00 → $450.00
2021-06-15 Buy Reiterated by Bank of America $396.08 $415.00
2021-06-14 Average - Neutral Target Raised by The Goldman Sachs Group $406.14 $246.00 → $436.00
2021-06-14 Buy Target Raised by Truist $406.14 $458.00 → $647.00
2021-06-11 Market Perform - Outperform Upgraded by Sanford C. Bernstein $396.64 $500.00
2021-06-10 Neutral - Buy Upgraded by UBS Group $414.71 $463.00
2021-06-10 Outperform Target Raised by SVB Leerink $414.71 $380.00 → $475.00
2021-06-08 Underweight - Neutral Upgraded by Atlantic Securities $395.37 $415.00
2021-06-08 Buy Target Raised by HC Wainwright $395.37 $305.00 → $452.00
2021-06-08 Buy Target Raised by Jefferies Financial Group $395.37 $450.00 → $500.00
2021-06-08 Sector Perform Target Raised by Royal Bank of Canada $395.37 $259.00 → $400.00
2021-06-08 Sell - Neutral Upgraded by Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell $395.37 $200.00 → $440.00
2021-06-08 Equal Weight Target Raised by Barclays $395.37 $265.00 → $395.00
2021-06-08 Buy Reiterated by HC Wainwright $395.37 $305.00 → $452.00
2021-06-08 Sell - Neutral Upgraded by Citigroup $395.37
2021-06-08 Market Perform - Outperform Upgraded by William Blair $395.37
2021-06-08 Overweight Target Raised by Morgan Stanley $395.37 $343.00 → $455.00
2021-06-07 Underperform - Market Perform Upgraded by Raymond James $395.85
2021-06-07 Market Perform - Outperform Upgraded by Cowen $395.85 $225.00 → $450.00
2021-06-07 Underperform - Neutral Upgraded by Bank of America $395.85 $235.00 → $400.00
2021-06-07 Underperform - Neutral Upgraded by Robert W. Baird $395.85 $216.00 → $382.00
2021-06-07 Underperform - Neutral Upgraded by Robert W. Baird $395.85
2021-05-24 Outperform Target Raised by Oppenheimer $278.86 $300.00 → $325.00
2021-05-18 Outperform Target Raised by Oppenheimer $281.01 $300.00 → $325.00
2021-04-26 Overweight Target Lowered by Morgan Stanley $269.46 $351.00 → $343.00
2021-04-23 Buy Reiterated by HC Wainwright $262.63
2021-04-19 Neutral Target Raised by Wedbush $269.05 $236.00 → $245.00
2021-04-19 Overweight Target Lowered by Morgan Stanley $269.05 $351.00 → $343.00
2021-04-12 Neutral Target Raised by Wedbush $262.80 $236.00 → $245.00
2021-02-17 Neutral Target Lowered by Cantor Fitzgerald $276.67 $278.00 → $268.00
2021-02-05 Buy - Hold Downgraded by DZ Bank $265.09 $264.00
2021-02-04 Outperform Target Lowered by SVB Leerink $267.39 $430.00 → $380.00
2021-02-04 Outperform Target Lowered by Credit Suisse Group $267.39 $350.00 → $338.00
2021-02-04 Outperform Target Lowered by Credit Suisse Group $267.39 $388.00 → $350.00
2021-02-04 Positive - Outperform Target Lowered by SVB Leerink $267.39 $430.00 → $380.00
2021-02-04 Buy Target Raised by HC Wainwright $267.39 $289.00 → $305.00
2021-02-04 Overweight Target Lowered by Morgan Stanley $267.39 $352.00 → $351.00
2021-02-03 Neutral Target Lowered by Piper Sandler $263.25 $265.00 → $250.00
2021-01-29 Hold - Buy Upgraded by Stifel Nicolaus $282.61 $258.00 → $358.00
2021-01-19 Overweight Target Lowered by Morgan Stanley $273.84 $357.00 → $352.00
2020-12-01 Market Perform Reiterated by William Blair $243.16
2020-12-01 Reduce - Sector Perform Target Raised by Royal Bank of Canada $243.16 $249.00 → $256.00
2020-11-19 Hold Reiterated by Royal Bank of Canada $244.01 $249.00
2020-11-19 Hold Reiterated by Royal Bank of Canada $244.01 $244.00 → $249.00
2020-11-19 Sector Perform Target Raised by Royal Bank of Canada $244.01 $244.00 → $249.00
2020-11-10 Buy Downgraded by Truist $236.34 $310.00 → $443.00
2020-11-10 Hold - Buy Upgraded by DZ Bank $236.34 $265.00
2020-11-09 Neutral Target Lowered by Mizuho $236.26 $282.00 → $244.00
2020-11-09 Outperform Target Lowered by Oppenheimer $236.26 $370.00 → $330.00
2020-11-09 Buy Target Lowered by HC Wainwright $236.26 $318.00 → $289.00
2020-11-09 Neutral - Underperform Downgraded by Bank of America $236.26 $240.00
2020-11-09 Outperform - Market Perform Downgraded by Cowen $236.26 $275.00 → $215.00
2020-11-09 Sector Perform Target Lowered by Royal Bank of Canada $236.26 $263.00 → $244.00
2020-11-09 Neutral - Underweight Downgraded by Atlantic Securities $236.26 $175.00
2020-11-05 Market Perform Upgraded by BMO Capital Markets $328.90 $280.00 → $343.00
2020-11-05 Positive - Outperform Target Raised by SVB Leerink $328.90 $342.00 → $402.00
2020-11-05 Buy Target Raised by Canaccord Genuity $328.90 $350.00 → $393.00
2020-11-04 Underperform - Neutral Upgraded by Bank of America $355.63 $230.00 → $360.00
2020-11-04 Equal Weight - Overweight Upgraded by Wells Fargo & Company $355.63 $437.00 → $390.00
2020-11-04 Hold - Buy Upgraded by Jefferies Financial Group $355.63 $450.00
2020-11-03 Target Lowered by Cantor Fitzgerald $247.01 $339.00 → $278.00
2020-10-28 Neutral Initiated by UBS Group $244.26 $268.00
2020-10-27 Neutral Target Lowered by Mizuho $255.30 $316.00 → $282.00
2020-10-22 Outperform Target Lowered by Oppenheimer $266.80 $360.00 → $340.00
2020-10-22 Buy Reiterated by HC Wainwright $266.80
2020-10-22 Outperform Target Lowered by Credit Suisse Group $266.80 $359.00 → $350.00
2020-10-22 Neutral Target Lowered by Wedbush $266.80 $281.00 → $244.00
2020-10-22 Equal Weight Target Lowered by Barclays $266.80 $275.00 → $265.00
2020-10-22 Overweight Target Raised by Morgan Stanley $266.80 $355.00 → $357.00
2020-10-20 Neutral Target Lowered by Piper Sandler $267.12 $270.00 → $265.00
2020-10-19 Sector Perform Target Lowered by Royal Bank of Canada $268.77 $281.00 → $268.00
2020-10-15 Underperform Target Lowered by Bank of America $280.63 $255.00 → $235.00
2020-10-13 Overweight Target Lowered by Morgan Stanley $291.46 $357.00 → $355.00
2020-09-29 Buy Reiterated by Canaccord Genuity $282.35 $396.00
2020-09-13 Hold Reiterated by JPMorgan Chase & Co. $269.91
2020-08-19 Outperform Target Lowered by SVB Leerink $279.98 $350.00 → $342.00
2020-08-07 Outperform Target Raised by Oppenheimer $305.71 $325.00 → $360.00
2020-08-07 Neutral - Outperform Upgraded by Credit Suisse Group $305.71 $270.00 → $375.00
2020-07-31 Sell Reiterated by Raymond James $274.69
2020-07-29 Hold Reiterated by JPMorgan Chase & Co. $277.36 $279.00
2020-07-27 Underweight - Overweight Upgraded by Morgan Stanley $286.19 $263.00 → $357.00
2020-07-10 Hold Reiterated by William Blair $278.88
2020-06-09 Outperform - Market Perform Downgraded by Sanford C. Bernstein $293.74 $360.00 → $297.00
2020-05-28 Sell Reiterated by Morgan Stanley $300.50 $301.00
2020-05-01 Neutral Target Lowered by Cantor Fitzgerald $293.09 $361.00 → $308.00

BIIB Stock Trend

The stock lies in the lower of a wide and falling trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $293.31 is broken, it will firstly indicate a stronger fall rate.

Given the current short-term trend, the stock is expected to fall -10.92% during the next 3 months and, with a 90% probability hold a price between $261.28 and $302.26 at the end of this 3-month period.

Data

Date Bottom Mid Top
2021-09-22 $292.65 $315.65 $338.65
2021-09-23 $291.99 $314.99 $337.99
2021-09-24 $291.33 $314.33 $337.33
2021-09-27 $290.67 $313.67 $336.67
2021-09-28 $290.01 $313.01 $336.01
2021-09-29 $289.35 $312.35 $335.35
2021-09-30 $288.69 $311.69 $334.69
2021-10-01 $288.03 $311.03 $334.03
2021-10-04 $287.37 $310.37 $333.37
2021-10-05 $286.71 $309.71 $332.71
2021-10-06 $286.05 $309.05 $332.05
2021-10-07 $285.38 $308.39 $331.39
2021-10-08 $284.72 $307.72 $330.73
2021-10-11 $284.06 $307.06 $330.06
2021-10-12 $283.40 $306.40 $329.40
2021-10-13 $282.74 $305.74 $328.74
2021-10-14 $282.08 $305.08 $328.08
2021-10-15 $281.42 $304.42 $327.42
2021-10-18 $280.76 $303.76 $326.76
2021-10-19 $280.10 $303.10 $326.10
2021-10-20 $279.44 $302.44 $325.44
2021-10-21 $278.78 $301.78 $324.78
2021-10-22 $278.12 $301.12 $324.12
2021-10-25 $277.46 $300.46 $323.46
2021-10-26 $276.80 $299.80 $322.80
2021-10-27 $276.14 $299.14 $322.14
2021-10-28 $275.48 $298.48 $321.48
2021-10-29 $274.82 $297.82 $320.82
2021-11-01 $274.16 $297.16 $320.16
2021-11-02 $273.50 $296.50 $319.50

About Biogen Inc.

Biogen Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders. It offers TECFIDERA, AVONEX, and PLEGRIDY to treat relapsing forms of multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn’s disease; and FAMPYRA to improve walking ability for patients with MS. The company also provides ELOCTATE to treat adults and children ... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT